SCHEMBL2633790

SCHEMBL2633790

CC(C)(C)OC(=O)N1CCC2(CC1)CCN(c1cnc(Cl)nc1)C2=O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.52
HRH3 Q9Y5N1 6/20 0.48
POLB P06746 1/20 0.41
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LIPE Q05469 1/20 0.38
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
GPR119 Q8TDV5 2/20 0.38
NPBWR1 P48145 1/20 0.38
MCHR1 Q99705 1/20 0.38
NAMPT P43490 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26101057 0.93 USP30 (0.60) USP30HRH3POLBOPRD1OPRK1
SCHEMBL18291496 0.84 USP30 (0.53) USP30HRH3OPRD1OPRK1MEN1
SCHEMBL30328066 0.81 USP30 (0.50) USP30HRH3MAPTLIPEGPR119
SCHEMBL17760752 0.81 USP30 (0.56) USP30HRH3GPR119NAMPT
SCHEMBL30919527 0.80 USP30 (0.53) USP30HRH3GPR119NAMPT
SCHEMBL2300710 0.79 HRH3 (0.54) USP30HRH3OPRD1OPRK1MEN1
SCHEMBL2478632 0.79 HRH3 (0.57) USP30HRH3MAPTLIPEGPR119
SCHEMBL31093400 0.79 POLB (0.46) POLBMEN1KMT2AMAPTTSHR
SCHEMBL18204085 0.77 GPR119 (0.56) POLBMEN1KMT2AMAPTTSHR
SCHEMBL2633811 0.77 USP30 (0.45) USP30HRH3GPR119NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9533995-B2 Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof SANOFI (FR) 2017-01-03 US disclosed
US-9533995-B2 Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof SANOFI (FR) 2017-01-03 US disclosed
US-20140315923-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-10-23 US disclosed
US-20140315923-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-10-23 US disclosed
US-20140315923-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-10-23 US disclosed
US-8796278-B2 Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof SANOFI (FR) 2014-08-05 US disclosed
US-8796278-B2 Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof SANOFI (FR) 2014-08-05 US disclosed
US-8796278-B2 Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof SANOFI (FR) 2014-08-05 US disclosed
EP-2569304-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-20 EP disclosed
US-20130059863-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-07 US disclosed
US-20130059863-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-07 US disclosed
US-20130059863-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-07 US disclosed
WO-2011143148-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-11-17 WO disclosed
WO-2011143148-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315923-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF CHRM2, NR3C2, NPSR1 USP30 4459/4885HRH3 7/4885POLB 4584/4885
US-20130059863-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF CHRM2, NR3C2, NPSR1 USP30 4459/4885HRH3 7/4885POLB 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.